Vitamin markets remain broadly stable, with most prices steady and contracts secured for early 2026. Minor moves — firmer tones in vitamin E and B3 — stand out, while elsewhere, demand is subdued and buying activity cautious as suppliers and buyers await new signals following the Chinese New Year.
Vitamin E 50%
Suppliers continue to push for higher prices or do not even offer at all. For example, in China, where buffering has been going on for the Chinese New Year holiday, that has led to a slightly firmer market. But in other regions the market is well contracted, and there is no need to buy material right now, leading to overall stable prices with sometimes a slightly firmer tone. With the majority of Q1 and a significant portion of Q2 already contracted, demand seems to be stagnating.
Vitamin A 1000
The market has experienced a prolonged period of stability at a low price point, with only minor regional variations in availability and pricing trends. Though some areas still show signs of weakness. Overall, the environment remains calm, and prices are consistent, with contracts in place for Q1 and a portion of Q2.
Vitamin D3 500
In recent weeks, the price of vitamin D3 500 has gradually decreased, yet it still remains at a relatively high level. The pace of this decline has slowed since last week, with suppliers beginning to resist further price reductions. Additionally, existing contracts from Q1 are still in play, while buyers continue to approach Q2 purchases with caution.
Vitamin B2 80%
Market participants express confidence in the current stability of prices. No anticipated changes in the near future are projected. Q1 and a portion of Q2 have been secured.
D-Calpan
Market activity remains minimal with prices generally stable to slightly declining across all major regions. Supply levels are reported as satisfactory, and suppliers are eager to uphold their market share. While contracts for the first quarter are finalised, opportunities for the second quarter largely remain open.
Vitamin B3
A firmer market has emerged, marked by reasonable buying activity observed in the past week and continuing this week. The price of vitamin B3 has dropped significantly in the past months, prompting suppliers to resist further declines and raise their prices recently. While the initial response was muted, buyers are now beginning to adopt longer-term positions, leading to a slight uptick in prices. Contracts for Q1 are secured, and a substantial portion of Q2 is also now committed.
Biotin
After a prolonged period of stable prices, there has been a recent decline in the price of both pure biotin and its diluted variants, such as biotin 2%. This price drop is attributed to a situation where supply exceeds demand across all regions. Since a significant portion of first-quarter contracts has already been fulfilled, there has not been a noticeable increase in buying activity at these reduced price points. Buyers are now exercising caution regarding longer-term purchases beyond the first quarter and are closely monitoring market developments.
Vitamin C 35% mono
Currently, the demand for vitamin C products remains limited, resulting in stable prices, with some cases experiencing slight declines. Market participants anticipate no significant changes until new demand emerges after the Chinese New Year. Given the low price levels, contracts for the first quarter and a substantial portion of the second quarter have already been secured.
